VK2735 is a dual GLP-1/GIP receptor agonist being developed for obesity in both injectable and oral forms.

How was VKTX performing before this surge?

The stock had been volatile and declining in recent weeks before this rally.

VKTX Stock Surges on Obesity Pipeline Optimism, Buyout Talk

Q: Is there buyout speculation around Viking Therapeutics?

Yes, speculation about a potential acquisition by a large pharmaceutical company has added momentum to the stock.

Viking Therapeutics (VKTX) stock posted its best daily performance in nearly three months, fueled by investor optimism over its lead obesity candidate VK2735 and buyout speculation.

June 24, 2026

2 min read

Source: Stocktwits

Key Numbers

price change

best day in nearly 3 months

Viking Therapeutics (VKTX) shares surged sharply in the latest trading session, recording their best daily performance in nearly three months. The rally reflects broader positive sentiment toward the company's obesity pipeline, particularly its lead candidate VK2735.

Potential Drivers

The move is attributed to growing optimism around VK2735, a dual GLP-1/GIP receptor agonist being developed in both injectable and oral formulations for obesity. Additionally, speculation about a potential acquisition by a large pharmaceutical company added further momentum.

Context

The surge comes after a period of volatility for the stock, which had declined in recent weeks. The obesity drug market is highly competitive, with major players like Novo Nordisk and Eli Lilly dominating, making any progress in this space closely watched by investors.

Similar Moves in the Sector

The obesity drug sector has seen increased investor interest, with similar rallies in other companies such as Altimmune and Structure Therapeutics, which also posted notable gains recently.

Frequently Asked Questions

The surge was driven by optimism over its lead obesity candidate VK2735 and buyout speculation.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.